Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.4152W HIGH $23.37
Volume
3.11 M
Value Traded
72.28 M
Short % Float
18.67%
Days to Cover
10.3
+0.35%Week
+67.03%1 Month
+45.45%3 Month
+68.36%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.04 B
EPS (TTM)
-0.68
P/E Ratio
-
Ent. Value
2.82 B
Total Shares
130.85 M
Float Shares
76.78 M
Insiders
40.42%
Institutions
90.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
SGRY Catalyst Timeline
Dated clinical, regulatory and corporate events for Surgery Partners, Inc.
Past FDA Catalysts and PDUFA Decisions
How SGRY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Surgery Partners, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SGRY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DeLuca TeresaDirector | Buy | 10,000 66,843 held | $14.35 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SGRY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 1.1 % (-21.4 %) | 10.89 M | 514.20 K | -37.82% ( -312.80 K) |
Ownership Trends
SGRY Short Interest
Shares sold short, counted twice a month.
18.67%
Short % of Float
of tradable shares sold short
14.3M
Shares Sold Short
-0.1% vs prior count
10.3 Very high
Days to Cover
trading days of normal volume to buy every short share back
1.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SGRY ranks across every disease it competes in
Competitive Position is a premium feature
See how SGRY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSGRY News
-SGRY
Oct 26, 2026▲ +47.6%on this news
HealthSpan Partners to Acquire Surgery Partners, Establishing a Leading Outpatient Surgical Care Platform
HealthSpan Partners announced it will acquire Surgery Partners in an all-cash deal valued at about $5.7 billion. This acquisition aims to create a prominent outpatient surgical care platform. The agreement highlights HealthSpan's strategy to enhance surgical care services.
Read more →-SGRY
Sep 17, 2026Surgery Partners Completes Sale of Ownership Interests in Idaho Falls Facilities to Intermountain Health; Updates Guidance to Include Impact of the Transaction
Surgery Partners has completed the sale of its ownership interests in Idaho Falls facilities to Intermountain Health for $797 million. This transaction is expected to enhance the company's long-term growth and improve its financial metrics, including reduced balance sheet leverage. The updated guidance for 2026 reflects the removal of these facilities from their operations.
Read more →-SGRY
Aug 10, 2026Surgery Partners, Inc. Announces Second Quarter 2026 Results Reaffirms Full Year 2026 Guidance
Surgery Partners, Inc. reported a 2.7% revenue increase for Q2 2026, with same-facility revenues up by 5.0%. Despite a net loss of $15.0 million, the company reaffirmed its full-year revenue guidance of $3.35 billion to $3.45 billion. The CEO highlighted strategic initiatives and the importance of the pending Idaho Falls transaction for financial optimization.
Read more →-SGRY
Jul 24, 2026Surgery Partners Announces Entry Into Agreement to Sell Ownership Interests in Idaho Falls Facilities to Intermountain Health; Reaffirms Guidance, Excluding Impact of Transaction
Surgery Partners, Inc. announced an agreement to sell its ownership interests in Idaho Falls facilities to Intermountain Health for approximately $795 million. The transaction, valued at $1.15 billion, is expected to enhance Surgery Partners' financial position and support its strategic focus on the ambulatory surgery center sector. However, completion is contingent on obtaining necessary approvals.
Read more →-SGRY
Jul 15, 2026Premier Plastic Surgery Partners Introduces Revolutionary Junera™ Regenerative Skin Treatment Across Partner Practices
Premier Plastic Surgery Partners has launched the Junera regenerative skin treatment across its network. Developed by Onyxa Medical, this innovative treatment utilizes advanced biostimulation technology to enhance skin quality and promote collagen remodeling. The initiative follows extensive evaluations by key opinion leaders within the organization, aiming to meet the growing demand for effective, long-lasting aesthetic solutions.
Read more →-SGRY
Jul 14, 2026PREMIER PLASTIC SURGERY PARTNERS APPOINTS HUGH O'NEILL TO LEAD CORPORATE DEVELOPMENT
Premier Plastic Surgery Partners has appointed Hugh O'Neill as Director of Physician Partnerships to drive corporate development and growth. O'Neill will collaborate with leadership to integrate plastic surgery practices while ensuring clinical autonomy. The organization aims to expand its national presence by partnering with top-tier practices committed to patient outcomes and innovation.
Read more →-SGRY
May 5, 2026Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance
Surgery Partners, Inc. reported a 4.5% increase in revenue for Q1 2026, totaling $810.9 million, despite a net loss of $35.9 million. The company reaffirmed its full-year revenue guidance of $3.35 billion to $3.45 billion and an Adjusted EBITDA of at least $530 million. CEO Eric Evans highlighted confidence in the company's growth strategy and operational management.
Read more →-SGRY
Apr 17, 2026Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details
Surgery Partners, Inc. has announced that it will release its first quarter 2026 earnings results on May 5, 2026, before the market opens. A conference call will follow at 8:30 a.m. Eastern Time, allowing investors to engage directly with the company's leadership. The call will be accessible via phone and webcast, with a replay available for a limited time.
Read more →-SGRY
Mar 12, 2026Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
Surgery Partners, Inc. appointed Lloyd Dean as an independent director. Dean, former CEO of CommonSpirit Health, is recognized for his efforts in healthcare leadership and public policy. His experience is expected to support Surgery Partners' mission of expanding high-quality outpatient surgical care.
Read more →-SGRY
Mar 9, 2026Surgery Partners, Inc. to Present at Upcoming Investor Conference
Surgery Partners, Inc. will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026. The event will allow investors to listen via a live webcast. The company, headquartered in Brentwood, Tennessee, focuses on high-quality outpatient surgical services and has over 200 locations across 30 states.
Read more →-SGRY
Mar 3, 2026▼ -12.3%on this news
Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2025 Results; Sets 2026 Guidance; Announces Share Repurchase Program
Surgery Partners, Inc. reported a 6.2% increase in full-year revenues for 2025, totaling $3.3 billion. Despite facing unexpected challenges in the fourth quarter, the company remains optimistic about future growth, particularly in higher-acuity procedures. They have also initiated a $200 million share repurchase program to enhance shareholder value. The company is focused on operational improvements and strategic initiatives for 2026.
Read more →-SGRY
Feb 24, 2026Surgery Partners, Inc. Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details
Surgery Partners, Inc. announced it will release its fourth quarter 2025 earnings on March 2, 2026. A conference call is scheduled for March 3, 2026, at 8:30 a.m. ET. Investors can join via dial-in or webcast, with a replay available for a limited time afterward.
Read more →-SGRY
Dec 11, 2025Surgery Partners, Inc. Announces Add-On Senior Notes Offering
Surgery Partners, Inc. announced an offering of $425 million in senior unsecured notes due 2032. The proceeds will be used for general corporate purposes, including repaying debt. This move reflects the company's ongoing growth strategy in the surgical services sector, despite potential market risks.
Read more →-SGRY
Dec 11, 2025SURGERY PARTNERS, INC. ANNOUNCES PRICING OF ADD-ON NOTES OFFERING
Surgery Partners, Inc. has announced the pricing of $425 million in senior unsecured notes due 2032 through its subsidiary, Surgery Center Holdings, Inc. The offering, which is set to close on December 16, 2025, aims to further the company's general corporate purposes, including debt repayment. The notes will be offered under specific regulations to qualified institutional buyers and non-U.S. persons. This follows the original issuance of $800 million of similar notes in April 2024.
Read more →-SGRY
Dec 11, 2025SURGERY PARTNERS, INC. ANNOUNCES ADD-ON SENIOR
Surgery Partners, Inc. announced its intention to offer an additional $425 million in 7.250% senior unsecured notes due 2032, through its subsidiary Surgery Center Holdings, Inc. The proceeds from this offering will be utilized for general corporate purposes, including repaying existing borrowings. As a leading healthcare services company, Surgery Partners aims to enhance its financial stability and support its ongoing operational expansion. However, the success of this offering is contingent on market conditions and carries some inherent risks.
Read more →-SGRY
Nov 10, 2025▼ -25.4%on this news
SURGERY PARTNERS, INC. ANNOUNCES THIRD QUARTER 2025 RESULTS
Surgery Partners, Inc. reported its Q3 2025 financial results showing a revenue increase of 6.6% year-over-year, reaching $821.5 million. Despite the growth in revenue and Adjusted EBITDA by 6.1%, the company also recorded a net loss of $22.7 million. The leadership indicated that softer-than-expected volume trends and changes in the payor mix influenced their decision to revise guidance for the year. Overall, the company remains committed to operational excellence amidst ongoing market challenges.
Read more →-SGRY
Aug 5, 2025SURGERY PARTNERS, INC. ANNOUNCES SECOND QUARTER 2025 RESULTS REAFFIRMS FULL YEAR 2025 GUIDANCE
Surgery Partners, Inc. reported an 8.4% increase in revenue for the second quarter of 2025, reaching $826.2 million, alongside a 9.0% rise in Adjusted EBITDA to $129.0 million. The Company reaffirmed its full-year guidance for revenue and Adjusted EBITDA, projecting them at $3.30 billion to $3.45 billion and $555 million to $565 million, respectively. Although the firm faced a net loss of $2.5 million this quarter, it continues to show operational growth and confidence in its strategic direction.
Read more →-SGRY
Jun 17, 2025▼ -12.3%on this news
SURGERY PARTNERS, INC. and Bain Capital Conclude Discussions
Surgery Partners, Inc. has concluded discussions with Bain Capital regarding a proposal for acquisition, with the Board reaffirming its confidence in the company's long-term growth as an independent entity. The Independent Committee, with advisory assistance, believes that sustaining the company as a publicly traded organization will generate greater value than pursuing the acquisition. The company has reiterated its revenue and EBITDA guidance for 2025, projecting strong performance across its operations driven by favorable market trends. Additionally, Surgery Partners plans an Investor Day in 2025 to outline its growth strategy and operational efficiencies.
Read more →-SGRY
May 12, 2025SURGERY PARTNERS, INC. ANNOUNCES FIRST QUARTER 2025 RESULTS REAFFIRMS FULL YEAR 2025 GUIDANCE
Surgery Partners, Inc. announced its financial results for the first quarter of 2025, indicating an 8.2% increase in revenue year-over-year. The company also reaffirmed its guidance for the full year 2025, with anticipated revenues and Adjusted EBITDA in the range of $3.30 billion to $3.45 billion and $555 million to $565 million, respectively. However, the company reported a net loss of $37.7 million for the quarter, and cash flows from operating activities decreased significantly compared to the previous year. Overall, the company maintains a positive outlook despite the loss, citing operational efficiencies and growth trends in the surgical sector.
Read more →-SGRY
Mar 3, 2025SURGERY PARTNERS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 RESULTS SETS 2025 GUIDANCE
Surgery Partners, Inc. announced its financial results for the fourth quarter and full year of 2024, showing significant revenue growth but also a substantial net loss. The company reported a 17.5% increase in revenue for Q4 and a 13.5% increase for the full year, alongside a rise in Adjusted EBITDA. Looking ahead, Surgery Partners projects revenue for 2025 to be between $3.30 billion to $3.45 billion, with expectations for continued growth despite challenges related to tax liabilities and net losses.
Read more →About Surgery Partners, Inc.
Headquarters340 SEVEN SPRINGS WAY, BRENTWOOD, TN
BIOPHARMAWATCH ELITE PLUS
Trade the next SGRY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime